Zobrazeno 1 - 10
of 537
pro vyhledávání: '"EGFR, Epidermal growth factor receptor"'
Autor:
Song Han, Gerik W. Tushoski-Alemán, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Zhiguang Huo, Jonathan Licht, Thomas J. George, Carmen Allegra, Jose G. Trevino, Steven J. Hughes
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 59, Iss , Pp 101070- (2025)
Oncogenic KRAS signaling plays a critical role in pancreatic ductal adenocarcinoma (PDAC) biology. Recent studies indicate that the combination of MEK and BCL-xL inhibition is synthetically lethal and holds promise for some types of solid cancers, ho
Externí odkaz:
https://doaj.org/article/191df517e9ab4a0b927c1c49c80b247d
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Epidermal growth factor receptor (EGFR) is an established driver gene in non-small cell lung cancer (NSCLC) and the common Exon 19 del mutation (p.E746_A750 del) has exhibited remarkable responses for EGFR tyrosine kinase inhibitors (TKIs). However,
Externí odkaz:
https://doaj.org/article/e2771ad19aef4f69ae8931e7a58efddb
Publikováno v:
Journal of Molecular Pathology, Vol 3, Iss 2, Pp 104-114 (2022)
The study aimed to demonstrate rapid and effective molecular testing on liquid-based cytology (LBC) samples for EGFR, KRAS and BRAF mutations using the Biocartis Idylla™. Rapid on-site evaluation (ROSE) LBC samples for patients with non-small cell
Externí odkaz:
https://doaj.org/article/1f9580dd3b17422fadf5895168bce2e1
Autor:
Rodolfo Chicas-Sett, Juan Castilla Martinez, Abrahan Hernández Blanquisett, Juan Zafra, Jorge Pastor-Peidro
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
The advent of targeted therapy has transformed the treatment paradigm and survival of patients with metastatic non-small cell lung cancer (NSCLC) with driver mutations. The development of acquired resistances during treatment with tyrosine kinase inh
Externí odkaz:
https://doaj.org/article/a34ed66a43744c97aae654393c0b59f4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Youming Lei, Kun Wang, Yinqiang Liu, Xuming Wang, Xudong Xiang, Xiangu Ning, Wanbao Ding, Jin Duan, Dingbiao Li, Wei Zhao, Yi Li, Fujun Zhang, Xiaoyu Luo, Yunfei Shi, Ying Wang, Depei Huang, Yuezong Bai, Hushan Zhang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Based on data analysis of 9649 Chinese primary NSCLC patients, we calculated the exact proportion of EGFR subtypes in NSCLC and evaluated the TMB level, PD-L1 expression level and tumor immune microenvironment among different EGFR mutation subtypes.
Externí odkaz:
https://doaj.org/article/24ceb5d835864657bd071c07447030d1
Autor:
Po-Fu Yueh, Yuan-Hao Lee, I-Tsang Chiang, Wei-Ting Chen, Keng-Li Lan, Cheng-Hsien Chen, Fei-Ting Hsu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundAnti-depressants have been reported to own anti-tumor potential types of cancers; however, the role of imipramine in non-small cell lung cancer (NSCLC) has not been elucidated. Epidermal growth factor receptor (EGFR) was known to be one of
Externí odkaz:
https://doaj.org/article/77734ca65ef2422badb51b352c6b83a3
Autor:
Silvia Valtorta, Alessia Lo Dico, Isabella Raccagni, Cristina Martelli, Valentina Pieri, Paolo Rainone, Sergio Todde, Bastian Zinnhardt, Elisabetta De Bernardi, Angela Coliva, Letterio S. Politi, Thomas Viel, Andreas H. Jacobs, Rossella Galli, Luisa Ottobrini, Valentina Vaira, Rosa Maria Moresco
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to
Externí odkaz:
https://doaj.org/article/f75ed0e8ab8b4392986f68e1fb538abb
Autor:
Mazza V, Cappuzzo F
Publikováno v:
The Application of Clinical Genetics, Vol Volume 10, Pp 49-56 (2017)
Valentina Mazza,1 Federico Cappuzzo1,2 1Department of Oncology-Hematology, 2Department of Medical Oncology, AUSL Romagna, Ravenna, Italy Abstract: The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-m
Externí odkaz:
https://doaj.org/article/de31f8e4ab0146dbb7d25fb6483a6992
Autor:
Leon P. Loevenich, Thomas Engleitner, Marlies Michl, Sebastian Vosberg, Matjaz Rokavec, Andreas Jung, Heiko Hermeking, Philipp A. Greif, Jens Neumann, Jörg Kumbrink, Roland Rad, Thomas Kirchner, Peter Jung, Rupert Öllinger, Sophie L. Boos
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 13, Iss 2, Pp 517-540 (2022)
Cellular and Molecular Gastroenterology and Hepatology
Cellular and Molecular Gastroenterology and Hepatology
Background & Aims Patient-derived tumor organoids recapitulate the characteristics of colorectal cancer (CRC) and provide an ideal platform for preclinical evaluation of personalized treatment options. We aimed to model the acquisition of chemotolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230937cfbfdbfc2312a8988f38a35f08
http://www.sciencedirect.com/science/article/pii/S2352345X21002228
http://www.sciencedirect.com/science/article/pii/S2352345X21002228